In case you didn't see the news late yesterday:

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) approved RituxanŽ (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).

"For the first time, people with Wegener's Granulomatosis and Microscopic Polyangiitis have a medicine that the FDA has approved for the treatment of these rare and relapsing diseases," said Hal Barron, M.D., chief medical officer and head, Global Product Development. "We are committed to following the science and focusing on diseases of high unmet medical need, including orphan conditions. Today's approval is an important example of how the scientific community can work together to advance science and treatment options for orphan diseases." ....

MORE>> FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis